|
Bortezomib as a Treatment Option in Patients With Waldenstrom Macroglobulinemia.
|
|
Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
|
|
Fcy Receptor Predictive Genomic Testing and the Treatment of Indolent Non-Hodgkin Lymphoma
|
|
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
|
|
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
|
|
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia.
|
|
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
|
